What if a cheap daily oral GLP-1 pill collapses branded drug pricing?
Trade the relative, not the index: a sub-$50 oral GLP-1 collapses branded pen/pill pricing — short Novo/Lilly and pen-device suppliers, long payers/PBMs and GLP-1-sensitive staples that re-rate on cheaper access. Rhymes with Sovaldi/Harvoni's Hep-C price collapse that gutted Gilead's franchise value. It is a disinflationary, intra-sector rotation — the tiny +growth_surprise risk-on cascade is immaterial and roughly the wrong frame, but harmless at this scale.
how we built this number — every step
The class rate is measured from our dated, sourced event library (decade-normalized Poisson — the full table is public at base_rates.json). The variant’s share within its class is the analyst’s editorial call, published so you can audit it. A wider range means thinner precedent. Full recipe: methodology · scored at Reality Check.
The butterfly cascade
How this trigger trickles across markets, left → right — the root shock, its first‑order moves, then the ripple effects. Drag any node; tap a market for its real price history.
Resolution timeline — how this probability is moving
Our model's odds (gold) over time vs the crowd's (Polymarket, blue), from the past toward the 1–3 years horizon. Each dot is a real macro event that nudged the probability — green pushed it up, red pushed it down. Tap a dot for the source. The gold path is an illustrative reconstruction anchored to today's estimate — real dated events, not a live re-estimate history.
What it would mean
If this plays out, it is a mixed shock. A sub-$50 once-daily generic-priced oral GLP-1 wins FDA approval, collapsing branded pill and injectable-pen pricing and gutting device-supplier margins. The trigger decomposes into signed root‑shocks — Growth surprise ▲ — which propagate through our causal graph to the markets below.
If it happens — the markets it would move
Biggest moves first. Projected moves are cascade-model priors; hist A–B% = what comparable past events actually did (measured abnormal returns), and model prior · unmeasured marks markets with no analogue backing yet. Tap any market for its price history.
| Market | Class | Projected move |
|---|
Historical precedent — what analogous events actually did
Across 40 analogous events (overlap‑weighted), as abnormal returns — market beta stripped, so it's the event's own effect, not the market backdrop. Shown at 20 days (persistent) and 5 days (immediate); ↺ fades = the two horizons disagree. Confidence = consistency × sample × significance.
| Asset | History says | Abnormal (20d · 5d) | Hit | n | Confidence | vs cascade |
|---|---|---|---|---|---|---|
| 10y yield DGS10 | LONG | +6bp · 5d +3bp | 65% | 40 | 0.23 | · |
| High-yield credit HYG | SHORT | -0.3% · 5d -0.1% | 62% | 40 | 0.18 | · |
| Volatility VIX | SHORT | -2.0% · 5d -6.8% | 60% | 40 | 0.15 | · |
| Bitcoin BTC | LONG | +6.3% · 5d -1.9% ↺ fades | 56% | 36 | 0.10 | · |
| Gold XAU | SHORT | -0.6% · 5d -0.8% | 55% | 40 | 0.08 | · |
| US dollar DXY | LONG | +0.1% · 5d -0.0% ↺ fades | 45% | 40 | 0.00 | · |
Why this probability
Sub-$50 generic oral GLP-1 in 1-3yr unlikely; patents/exclusivity wall protects branded pricing. A base‑rate‑anchored prior, continuously scored against what actually happens — not a forecast.